Last updated: May 15, 2026
Ciprofloxacin extended-release (ER) is an older fluoroquinolone franchise with limited recent trial momentum versus immediate-release ciprofloxacin and newer respiratory and urology antibiotics. Market opportunity in the US is constrained by generic saturation and by clinical preference for established immediate-release regimens where efficacy and safety data are comparable. Current commercial leverage is most likely to come from (1) incremental label expansions, (2) line extensions in dosing or formulation variants, and (3) targeted geographies or institutional channels where extended dosing improves adherence.
No current, active phase-by-phase clinical trial dataset with drug-specific identifiers (NCT numbers tied to ciprofloxacin ER) is provided in the request context, and no FDA regulatory dossier identifiers (NDA/BLA) or Orange Book listing identifiers are supplied. Without those inputs, a precise, date-stamped clinical-trials update and legally usable exclusivity or patent-expiry-driven launch projection cannot be produced.
What clinical trials are ongoing for ciprofloxacin extended-release?
A full update requires trial identity (NCT number), development phase, indication, design (randomization, comparator), and enrollment status, plus whether the sponsor is pursuing a 505(b)(2) or a novel NDA pathway. The requested information cannot be generated accurately without those drug-specific trial identifiers and endpoints.
What phase 1, phase 2, and phase 3 endpoints are used for ciprofloxacin ER?
In ciprofloxacin development more broadly, extended-release programs typically focus on pharmacokinetics (Cmax, Tmax, AUC), food effects, tolerability, and clinical cure or eradication endpoints by infection type. For urogenital indications, endpoints often map to culture-confirmed microbiological response and clinical resolution. For skin or respiratory indications, clinical cure and microbiological eradication are common.
No drug-specific trial slate is available from the request content to confirm which endpoints are currently being used for ciprofloxacin ER.
Which company sponsors ciprofloxacin ER trials?
Sponsor identification depends on trial registry entries that must be tied to ciprofloxacin extended-release specifically. No sponsor roster is provided in the request context.
How big is the ciprofloxacin extended-release market today?
Market drivers
Ciprofloxacin ER competes against:
- Generic immediate-release ciprofloxacin tablets and generics in multiple dose forms.
- Other fluoroquinolones and alternative classes for common indications (uncomplicated UTI, complicated UTI, prostatitis, respiratory off-label use).
- Health-system antimicrobial stewardship and payer-driven formulary placement favoring lowest-cost effective regimens.
ER’s theoretical advantage is adherence and dosing convenience. In practice, US formularies often standardize around cheapest generics and established dosing schedules. That compresses premium pricing and reduces willingness to switch.
Market constraint
Without indication- and formulation-specific sales data, the market size can only be described directionally. The practical ceiling for ciprofloxacin ER is typically set by:
- The extent of generic competition in the same therapeutic category and dose form.
- Whether payers reimburse ER at parity or require step therapy.
- Whether clinical guidelines prefer immediate-release regimens for safety and dosing flexibility.
No market figures, patient incidence, or payer adoption metrics are provided in the request context, so a quantified market size or share forecast would be speculative.
When does ciprofloxacin extended-release lose exclusivity and when could generics enter?
A credible exclusivity and generic-entry timeline requires:
- The specific FDA product (NDA number, proprietary name, dosage strength) and Orange Book entries.
- Patents and exclusivity codes (drug substance, drug product, use).
- Expiration dates and any pediatric exclusivity adjustments.
- Whether Paragraph IV certifications exist and whether settlements occurred.
No NDA/proprietary product identity or Orange Book listing is included in the request. A date-based timeline cannot be produced accurately.
What is the Orange Book status of ciprofloxacin extended-release?
Orange Book status is product-specific. It requires listing extraction for the exact ER ciprofloxacin NDA and dosage form. The request does not include the NDA number, proprietary name, or a list of Orange Book patents, so listing status and expiration dates cannot be stated.
What patents protect ciprofloxacin extended-release formulations and methods of use?
Patent coverage also requires product identity and patent list extraction. Ciprofloxacin ER estates, where they exist, usually include combinations covering:
- Sustained-release matrix composition or coatings.
- Methods of treating specific infections or achieving dosing schedules.
- Manufacturing processes for extended-release characteristics.
No patent numbers, assignees, or jurisdiction coverage is supplied in the request content, so an actionable patent-protection map cannot be generated.
How strong is the patent estate for ciprofloxacin ER vs immediate-release ciprofloxacin?
Strength is measured by:
- Count of unexpired patents per jurisdiction.
- Claims breadth (composition vs formulation vs method-of-use).
- Litigation history and obviousness/enablement risk.
- Practical design-around barriers (release kinetics, excipient systems, manufacturing parameters).
No patent datasets are included in the request context, so a comparative strength analysis cannot be executed.
Which companies are challenging ciprofloxacin extended-release via Paragraph IV?
Paragraph IV risk assessment needs:
- Certified ANDA(s) and the applicant names.
- Patent numbers listed for certification.
- Submission dates and district court filings.
- Settlement terms and effective dates.
No ANDA applicant or litigation docket information is provided, so this cannot be generated.
What generic entry risks exist for ciprofloxacin ER by geography (US, EU, UK, Canada)?
A cross-geography risk model requires:
- Regulatory status for each region (marketing authorization numbers, assessment reports).
- Timing of exclusivity/patent expirations in each jurisdiction.
- Local guidance on sustained-release equivalence and bioequivalence requirements.
No region-by-region regulatory identifiers are supplied, so only non-actionable generalities can be offered, which the constraints do not permit.
What formulation patents could block ciprofloxacin ER generic manufacturing?
In sustained-release systems, typical IP blockers are:
- Proprietary controlled-release polymer blends.
- Matrix geometry, particle sizing, and manufacturing steps that affect release profile.
- Coating technologies that control drug diffusion and erosion.
However, a block-by-block analysis requires the actual listed patents and claim language tied to the ER product.
How does ciprofloxacin extended-release compare with ciprofloxacin immediate-release on efficacy and safety?
General fluoroquinolone safety signals include class-related risks. Extended-release does not remove class limitations. Efficacy comparisons depend on whether ER reaches the same or target exposure profile and whether clinical outcomes are comparable in the studied indications.
A rigorous comparison needs:
- Head-to-head or matched exposure PK/PD analyses.
- Clinical endpoints from ER trials versus IR trials.
- Adverse event rates and discontinuation patterns by grade.
No ER-specific clinical results are provided in the request content, so a data-backed comparison cannot be completed.
Clinical trial update: what would a realistic 12–36 month launch projection look like for ciprofloxacin ER?
A projection depends on:
- Regulatory pathway (505(b)(2) vs ANDA).
- Whether the sponsor is pursuing new indications or only line maintenance.
- Remaining exclusivity and patent barriers.
- Anticipated label scope and formulary positioning.
Because the request does not include the exact product identity, the projection cannot be translated into an actionable schedule for generic entry or brand retention.
Key Takeaways
- Ciprofloxacin ER’s commercial path is constrained by generic competition and by payer preference for lowest-cost effective regimens, limiting upside absent a label expansion or differentiated dosing advantage with strong clinical or adherence evidence.
- A precise clinical trials update and a date-based generic-entry projection require product-specific identifiers (FDA NDA/proprietary name, Orange Book listings, and trial registry entries tied to ciprofloxacin ER).
- Without those identifiers, no accurate exclusivity calendar, patent-expiry-driven launch forecast, or litigation/Paragraph IV risk assessment can be produced.
FAQs
- Is ciprofloxacin extended-release FDA-approved for which specific indications?
- What NCT trials are currently recruiting for ciprofloxacin extended-release, and what are their endpoints?
- Does ciprofloxacin ER have any FDA exclusivity or listed patents that affect ANDA filing timelines?
- How do PK exposure targets for ciprofloxacin ER compare with immediate-release ciprofloxacin?
- What is the most likely generic launch timing scenario for ciprofloxacin ER under US Paragraph IV litigation?
References
- APA formatting requires specific sources, but no citable trial registry IDs, FDA Orange Book listings, or NDA identifiers were provided in the request context.
